Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Depomed Acquires U.S. Rights to Late-Stage, First-in-Class Pain Product from Grunenthal

NEWARK, Calif., Nov. 17, 2015 /PRNewswire/ — Depomed, Inc. (NASDAQ: DEPO) today announced that it has entered into a definitive agreement to acquire the U.S. and Canadian rights to cebranopadol and its related follow-on compound from Grünenthal GmbH (“Grünenthal”). Cebranopadol is a novel, first-in-class analgesic in development for the treatment of moderate to severe chronic nociceptive […]

Read More »

AstraZeneca’s Tagrisso to cost $12,750 for a month’s supply

AstraZeneca’s new lung cancer pill Tagrisso, which won early U.S. approval on Friday, will cost $12,750 for a month’s supply.   A company spokeswoman said on Tuesday the wholesale acquisition cost was comparable to other targeted oral lung cancer therapies, such as Pfizer’s Xalkori and Novartis’ Zykadia. AstraZeneca has previously said it believes Tagrisso could generate […]

Read More »

How Vertex’s Long-Term $500K Gamble Paid Off with a $30 Billion Return

November 17, 2015By Mark Terry, Breaking News Staff   Boston-based Vertex Pharmaceuticals (VRTX) presents an unusual business model one that has been the focus of a Harvard case study. In short, in 2001 the company took a relatively small grant from the Cystic Fibrosis Foundation and spun it into a highly successful development program. […]

Read More »

Alcoholism drug can wake up dormant HIV to be killed, study finds

Scientists seeking a cure for the AIDS virus have made an unexpected discovery with a drug designed to combat alcoholism which they say could be a critical part of a strategy to “wake up” and then kill dormant HIV hiding in the body. The drug, branded as Antabuse but also sold as a generic called […]

Read More »

FDA approves J&J drug for advanced multiple myeloma

U.S. regulators have approved an experimental treatment from Johnson & Johnson that may offer hope to multiple myeloma patients who have run out of other options against the blood cancer. The U.S. Food and Drug Administration on Monday said it had approved Darzalex (daratumumab) for patients who had already undergone at least three prior standard […]

Read More »

Dassault Systèmes Launches Three Industry Solution Experiences for Life Sciences

Pharmaceutical and Biotechnology Companies Can Now Digitally Transform Therapeutic Innovation   VELIZY-VILLACOUBLAY, France — November 16, 2015 — Dassault Systèmes (Euronext Paris: #13065, DSY.PA), the 3DEXPERIENCE Company, world leader in 3D design software, 3D Digital Mock Up and Product Lifecycle Management (PLM) solutions, today announced the launch of three industry solution experiences for life sciences, […]

Read More »

FDA approves Baxalta’s drug for rare bleeding disorder

The U.S. Food and Drug Administration said on Friday it approved Baxalta Inc’s drug for use in patients with a type of rare bleeding disorder. The drug, Adynovate, was approved to control and reduce the frequency of bleeding episodes in patients with Hemophilia A, the agency said in a statement. Data from a late-stage study, […]

Read More »

U.S. approves AstraZeneca’s potential $3 billion lung cancer pill

A new lung cancer pill from AstraZeneca, designed for patients whose disease has worsened after treatment with other therapies, was approved by U.S. regulators on Friday, in a boost for the British drugmaker.   Tagrisso, also known as AZD9291, is one of several cancer medicines AstraZeneca hopes will rebuild its sales following patent losses on […]

Read More »

Roche Exiting Four Manufacturing Sites in Europe and the U.S.,1,200 Jobs Impacted

November 12, 2015By Alex Keown, Breaking News Staff   BASEL, Switzerland – Roche (RHHBY) will vacate four manufacturing sites in the United States and Europe, displacing approximately 1,200 employees as part of a restructuring effort for the manufacturing of its small molecule products, the company announced Thursday. The move comes as Swiss-based Roche addresses […]

Read More »

U.S. FDA approves Gilead’s hepatitis C drug for expanded use

Drugmaker Gilead Sciences Inc said on Thursday the U.S. Food and Drug Administration had approved the expanded use of its blockbuster hepatitis C drug, Harvoni.   The drug can now be used to treat patients with subtypes of chronic hepatitis C virus (HCV) and patients who are co-infected with Human Immunodeficiency Virus (HIV), Gilead said […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!


Ad Right Bottom